Evaxion Biotech A/S
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Evaxion Biotech A/S generated cash of -$17,691,000, which is more than the previous year. Cash used in financing activities reached the amount of $10,691,000 last year. Net change in cash is therefore -$7,601,000.
Cash Flow
| 2018 | -1.99M | 6K | 9.02M |
|---|---|---|---|
| 2019 | -7.02M | -61K | 9.50M |
| 2020 | -12.43M | -393K | 8.81M |
| 2021 | -21.93M | -1.33M | 49.80M |
| 2022 | -25.77M | -268K | 7.85M |
| 2023 | -17.69M | -93K | 10.69M |
EVAX Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 13.18M | 32.16M | 5.83M | 9.55M | 7.43M | 468K |
Operating activities | ||||||
Net income | -22.12M | -23.16M | -24.53M | -15.01M | -11.19M | -5.53M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 615K | 571K | 344K | 105K | 81K | 74K |
Stock-based compensation expense | 479K | 942K | 1.37M | 3.40M | 2.36M | 0 |
| Deferred income tax benefit | 479K | 942K | 1.37M | 3.40M | 2.36M | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 1.10M | -1.48M | 1.86M | -2.51M | -337K | 443K |
Inventories | 0 | 1.48M | -1.86M | 2.51M | 403K | 446K |
Accounts payable | 502K | -599K | -647K | 1.79M | 507K | 79K |
Cash generated by operating activities | -17.69M | -25.77M | -21.93M | -12.43M | -7.02M | -1.99M |
Investing activities | ||||||
Purchases Of Investments | -6K | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -87.13K | -292K | -1.36M | -393K | -61K | -7K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -93K | -268K | -1.33M | -393K | -61K | 6K |
Financing activities | ||||||
Common Stock Issued | 9.16M | 428K | 53.85M | 9.02M | 9.44M | 1.09M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -632K | 7.42M | -289K | -74K | 79K | -63K |
Cash used in financing activities | 10.69M | 7.85M | 49.80M | 8.81M | 9.50M | 9.02M |
Net Change In Cash | -7.60M | -18.98M | 26.33M | -3.72M | 2.12M | 6.96M |
Cash at end of period | 5.58M | 13.18M | 32.16M | 5.83M | 9.55M | 7.43M |
| Data source | Data source | Data source | Data source |